Medical Developments International's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.00.
During the past 3 years, the average EBIT per Share Growth Rate was 57.30% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 8.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
MDDVF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -134 Med: -17 Max: 63.7
Current: 57.3
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Medical Developments International was 63.70% per year. The lowest was -134.00% per year. And the median was -17.00% per year.
MDDVF's 3-Year EBIT Growth Rate is ranked better than 91.36% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs MDDVF: 57.30
Medical Developments International (OTCPK:MDDVF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Medical Developments International EBIT per Share Related Terms
Medical Developments International EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medical Developments International (MDDVF) has a EBIT per Share of $-0.00 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medical Developments International and its competitors. According to the industry distribution chart, Medical Developments International ranks #70 out of 810 companies in the Drug Manufacturers industry, placing it in the top 8.6%.
Is Medical Developments International's EBIT per Share too high?
Medical Developments International's current EBIT per Share is $-0.00. Based on the distribution chart, Medical Developments International ranks #70 out of 810 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Medical Developments International has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medical Developments International's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medical Developments International ranks #70 out of 810 companies for EBIT per Share. This places Medical Developments International in the top 9% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medical Developments International and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medical Developments International's current EBIT per Share is $-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medical Developments International stock overvalued right now?
Based on GuruFocus' analysis, Medical Developments International (MDDVF) is currently considered Fairly Valued. The stock's GF Value™ is $0.39, compared to a current price of $0.37 — trading 5.1% below its estimated fair value. The current EBIT per Share is $-0.00. Medical Developments International's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Medical Developments International (MDDVF), the current EBIT per Share is $-0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medical Developments International (MDDVF) Overvalued in 2026?
Based on GuruFocus' analysis, Medical Developments International stock appears to be undervalued.
The current stock price of $0.37 is trading 5.1% below its estimated GF Value™ of $0.39.
GuruFocus considers Medical Developments International to be Fairly Valued.
Key valuation signals for MDDVF:
EBIT per Share: $-0.00
GF Value™: $0.39 vs. price of $0.37 (5.1% below fair value)
No single metric tells the full story. See the MDDVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medical Developments International Business Description
Medical Developments International Ltd is a specialized healthcare company. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The segments of the company are Pain Management and Respiratory. The company derives maximum revenue from the Pain management segment.
51GF Score
Get the complete analysis for MDDVF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDDVF has been successfully added to your 
